News

Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill.

July 7 (Reuters) - The weight-loss drug market is booming, with biotech firms racing to capture a slice of a fast-growing sector dominated by Novo Nordisk and Eli Lilly.

Agios stock skyrocketed closer to a profit-taking zone Tuesday after the FDA assigned its sickle cell drug a speedy review.

AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.

Healthcare has become Wall Street’s bargain bin in 2026, and value hunters are starting to pay attention. Drug pricing reform, patent cliffs and post-COVID-19 hangovers have crushed multiples across Big Pharma, but the wreckage has created opportunities in two cash-generative franchises trading at single-digit forward earnings multiples. Heading into July, Novo Nordisk and Pfizer stand ... 2 Dirt Cheap Healthcare Stocks to Buy in July

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.

European stocks are having their loudest year in a decade, and the Vanguard FTSE Europe ETF (NYSEARCA:VGK) is the vehicle most retail investors will consider. VGK trades around $90, up 18% over the past year, while every US finance headline focuses on hyperscaler capex and AI compute. If you want to bet that the next ... The Anti-Magnificent Seven Trade? VGK Is Quietly Creeping Toward Record Highs

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

European equities traded in the US as American depositary receipts were tracking modestly higher lat

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Peptides are short-chain amino acids that are formulated into drugs. Insulin is a peptide. Legions of other peptides are on the market in the “wellness” industry, promoted for everything from athletic performance to skin care, mental focus, and “romantic connection”—the latter pitched by a startup called Feel Peptides.

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

The stock is known to soar on good news.

Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.

Novo Nordisk stock has delivered a decline of 32.7% over the past three years, yet current valuation work, including a Discounted Cash Flow (DCF) intrinsic value estimate and market multiple checks, both point to the shares trading at a discount to what the business may be worth. The three-year return of 32.7% down raises the question of whether sentiment has moved further than the underlying value of Novo Nordisk. Medicare’s decision to cover certain GLP-1 weight loss drugs and growing use...

The new unit will start with $2.5 billion to help companies choose and use AI tools.

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has gained more than 15% over the past month, mainly driven by the stock’s inclusion in the Russell 3000 index and strong Q1 2026 earnings. Wall Street expects more than 21% upside over the next 12-months making Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) one of the Best Rising Penny Stocks to Buy According […]

NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.

Market research highlights Novo Nordisk (NYSE:NVO) as a leading company in the global antidiabetic drugs market. The report points to rising diabetes prevalence and new therapeutic approaches as key drivers for the sector. Novo Nordisk is identified as a major participant in advanced drug classes, including GLP-1 receptor agonists. Novo Nordisk is a central player in a global antidiabetic market that research identifies as having significant long-term potential, with diabetes prevalence and...

Novo Nordisk stock has given investors a mixed ride over the past few years, with a 36.1% gain over 5 years but weaker recent returns, and the valuation checks now suggest the shares may lean cheap rather than fully priced in. Over the last 5 years, Novo Nordisk has returned 36.1%, which points to a longer term story that still created value even though shorter term performance has been more muted. Recent headlines around Medicare’s GLP-1 Bridge program and expanding cardiometabolic research...

The new company will focus on integrating enterprise AI, offering tailored support and protecting client data and intellectual property.

Microsoft shares soar as the behemoth announces a $2.5 billion investment in a new initiative, Microsoft Frontier Co. But does that warrant buying MSFT stock today?

Microsoft (MSFT) is launching a new business unit with a $2.5 billion investment that will help clie

European stock markets closed higher Thursday, paced by defense and luxury goods, while oil prices f

LLY's leadership in GLP-1 therapies, expanding pipeline and diversified growth strategy support its long-term outlook despite a premium valuation.

Medicare is now covering weight-loss drugs for some seniors, in a win for patients. For Wall Street, the math is trickier.

Millions of Medicare beneficiaries will gain access to obesity drugs for the first time starting Wednesday under CMS’ temporary Bridge program, a federal initiative designed to expand GLP-1 obesity drug coverage for eligible seniors at a $50 monthly copay. The...

In the latest trading session, Novo Nordisk (NVO) closed at $48.77, marking a +1.73% move from the previous day.

A Barchart report today shows unusually heavy volume in out-of-the-money (OTM) put options in Novo Nordisk, which makes Ozempic and Wegovy. NVO stock has been moving up, so is it overvalued now?